Stifel Nicolaus Cuts Sage Therapeutics (NASDAQ:SAGE) Price Target to $6.00

Sage Therapeutics (NASDAQ:SAGE) had its price objective decreased by Stifel Nicolaus from $10.00 to $6.00 in a research note released on Monday morning,Benzinga reports. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. Bank of America reduced their price target on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research report on Wednesday, October 9th. Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research report on Thursday, November 21st. StockNews.com downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. TD Cowen reduced their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, November 21st. Finally, Wedbush reduced their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 9th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.53.

Sage Therapeutics Trading Down 4.6 %

SAGE opened at $5.03 on Monday. The company has a fifty day simple moving average of $6.15 and a 200 day simple moving average of $8.26. The firm has a market cap of $307.70 million, a price-to-earnings ratio of -0.90 and a beta of 0.87. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The firm had revenue of $11.87 million for the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. Sage Therapeutics’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same period in the previous year, the business posted ($2.81) earnings per share. On average, analysts forecast that Sage Therapeutics will post -6.53 earnings per share for the current fiscal year.

Institutional Trading of Sage Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC raised its position in shares of Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 2,782 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares during the last quarter. Quest Partners LLC grew its stake in shares of Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after purchasing an additional 1,486 shares during the last quarter. Creative Planning acquired a new position in shares of Sage Therapeutics in the 3rd quarter worth approximately $88,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Sage Therapeutics in the 2nd quarter worth approximately $153,000. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.